-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Initiates Coverage On Odyssey Therapeutics with Outperform Rating, Announces Price Target of $30

Benzinga·06/02/2026 13:11:38
Listen to the news
Wedbush analyst David Nierengarten initiates coverage on Odyssey Therapeutics (NASDAQ:ODTX) with a Outperform rating and announces Price Target of $30.